6:25 PM
 | 
Dec 12, 2012
 |  BC Extra  |  Company News

KV, Hologic settling Makena claims

KV Pharmaceutical Co. (OTCQB:KVPHQ) will pay Hologic Inc. (NASDAQ:HOLX) $60 million by year end to settle all claims related to preterm birth drug Makena hydroxyprogesterone caproate. KV, which has rights to the long-acting 17p from Hologic, filed for Chapter 11 bankruptcy...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >